Yen-Chu Lin obtained his PhD from ETH Zurich (Switzerland) working at Gisbert Schneider lab where he pioneered in the peptide research field adopting machine learning approaches combining with experimental-lead strategies or with pharmacology-driven concepts to multidimensionally design peptides with desired activities and selectivity.

His post-doc with Sir David Lane and Gregory Verdine focused on developing peptides and mini-proteins targeting critical protein-protein interaction in cancers by diversity-oriented biological techniques.

He has published several influential papers in high-impact journals in computational chemistry and chemical biology field. In 2018 he joined Insilico Taiwan, as CSO leading the research efforts in the company.

He now assumes the role of CEO of Insilico Taiwan looking after RD and BD activities of Insilico Medicine in Asia markets.

He holds bachelor's degree in pharmacy and chemistry and master's degree in pharmacology both from National Taiwan University